| Literature DB >> 23222525 |
Anthony E Pusateri1, Richard B Weiskopf, Vikhyat Bebarta, Frank Butler, Ramon F Cestero, Irshad H Chaudry, Virgil Deal, Warren C Dorlac, Robert T Gerhardt, Michael B Given, Dan R Hansen, W Keith Hoots, Harvey G Klein, Victor W Macdonald, Kenneth L Mattox, Rodney A Michael, Jon Mogford, Elizabeth A Montcalm-Smith, Debra M Niemeyer, W Keith Prusaczyk, Joseph F Rappold, Todd Rassmussen, Francisco Rentas, James Ross, Christopher Thompson, Leo D Tucker.
Abstract
A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23222525 DOI： 10.1097/SHK.0b013e318280409a
Source DB: PubMed Journal: Shock ISSN： 1073-2322 Impact factor: 3.454